Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. [electronic resource]
Producer: 20130731Description: 828-60 p. digitalISSN:- 1543-2165
- Humans
- Adenocarcinoma -- drug therapy
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents -- therapeutic use
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Gefitinib
- Genetic Testing
- Lung Neoplasms -- drug therapy
- Molecular Diagnostic Techniques -- methods
- Molecular Targeted Therapy
- Patient Selection
- Protein Kinase Inhibitors -- therapeutic use
- Quinazolines -- therapeutic use
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Systematic Reviews as Topic
No physical items for this record
Publication Type: Journal Article; Practice Guideline
There are no comments on this title.
Log in to your account to post a comment.